First-In-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

December 2011 in “ Journal of clinical oncology ”

Timothy A. Yap, Yan Li, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos P. Papadopoulos, Richard D. Baird, Liliana Delgado, Akosha Taylor, Lisa C. Lupinacci, Ruth Riisnaes, Lorna Pope, Simon P. Heaton, George V. Thomas, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher

pan-AKT inhibitor MK-2206 skin rash stomatitis phosphorylated AKT hair follicles

TLDR MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

The first-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in 33 patients with advanced solid tumors established the maximum-tolerated dose at 60 mg due to dose-limiting toxicities like skin rash and stomatitis. MK-2206 was generally well-tolerated and showed evidence of AKT signaling blockade, with significant declines in phosphorylated AKT in tumor biopsies and suppression in hair follicles. Preliminary antitumor efficacy was observed, including a notable case of a patient with pancreatic adenocarcinoma showing a 60% decrease in cancer antigen 19-9 levels and 23% tumor shrinkage. The results supported further rational combination trials to enhance clinical benefits.

View this study on ascopubs.org →

Discuss this study in the Community →

Research cited in this study

1 / 1 results

research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

65 citations, February 2011 in “Molecular cancer therapeutics”

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Similar Research

5 / 1000+ results

First-In-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Research cited in this study

research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Related Community Posts Join

community What is the options after unsuccessful dut+minox 2x a day?

community Shiseido/Replicel RCH-01 trial results were finally shared online

community 7 months. propecia oral Topical minoxidil. Drama Penn once a week.

community First time visiting a dermatologist for hairloss, I'm skeptical

community Breezula CB-03-01

community Wouldn’t it be funny if there already was a drug that existed which reactivated sleeping follicles? It would be our own version of Ozempic

Similar Research

research Inhaled Medicines for Targeting Non-Small Cell Lung Cancer

research Water Extract of Cacumen Platycladi Promotes Hair Growth Through the Akt/GSK3β/β-Catenin Signaling Pathway

research Drug Repurposing: Hypothesis, Molecular Aspects, and Therapeutic Applications

research Integrin Signaling Regulates YAP/TAZ to Control Skin Homeostasis

research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance